EAEU Transition Protocol Timeline: Four Postponements and New Deadlines

1. Key takeaways

The full switch of the Eurasian Economic Union medical device single market has been postponed four times. The protocol signed on December 30, 2021 set the national-rules application deadline at December 31, 2026; the protocol signed on December 29, 2025 moved it to December 31, 2027, and pushed the end of management under national rules to December 31, 2028. The publicly stated reason for the postponements is that member states need more time to complete the switch and avoid shortages of already-registered product categories.

For manufacturers, the operative consequence is a two-year runway rather than an open-ended transition. National applications remain possible only through the end of 2027, and the national rules framework itself survives through the end of 2028 for legacy management. Planning assumptions that rely on a further postponement carry structural risk, because each extension to date has required a formal protocol amendment and, in Russia’s case, ratification through federal law No. 288-ФЗ on August 4, 2026 — observable, slow-moving events that cannot be assumed in advance.

The postponement history also illustrates how transition deadlines should be read as policy instruments rather than purely technical milestones. Each extension traded regulatory ambition for supply continuity, and each was negotiated among member states with different industrial bases and import dependencies. For a manufacturer, the practical reading is that the current dates are stable enough to plan against but not certain enough to bet the portfolio on. The recommended posture keeps both dimensions active: operational plans that assume December 31, 2027 and December 31, 2028 hold, and a lightweight monitoring function that detects early signals of another adjustment. The cost of maintaining such monitoring is minimal compared with the cost of a compressed re-planning exercise triggered by an unexpected amendment.

2. Legal basis

The transition timeline is defined by Article 11 of the 2014 Agreement as amended by successive protocols, together with the domestic acts through which the Russian side implemented the latest extension. The table below lists the relevant instruments.

3. Expert insights

Insight one: each postponement of the transition period is part of a systematic action. Every extension has been accompanied by synchronized renewal of member-state domestic rules — in this round, the Russian side’s Resolution No. 2214. This paired movement of the international treaty layer and the domestic rules layer is the first signal source for judging the next adjustment. Manufacturers who monitor both layers in parallel will see a coming change months before it is formally announced, because the domestic draft acts and the protocol negotiation process leave a documentary trail.

Insight two: the protocol’s entry-into-force mechanism carries built-in uncertainty. The protocol applies provisionally 10 days after signing; formal entry into force requires all member states to complete domestic procedures and deliver the final written notification. The Russian side completed ratification through federal law No. 288-ФЗ, and Belarus completed parliamentary approval on June 3, 2026; the progress of the remaining member states must be re-checked before submission. A submission made while the protocol is only provisionally applied is legally valid, but the applicable regime at later stages should be confirmed against the formal status at that time.

Insight three: plan on a baseline scenario rather than betting on another delay. Treating a further extension as the default assumption will leave manufacturers exposed in the final six months before the window closes. The reasonable approach is to schedule production and submissions against the current deadlines while running Union-rules material preparation as a parallel task. This costs some duplication of effort, but it converts the transition from a cliff-edge event into a managed migration with contingency options already prepared.

Another dimension worth institutionalizing is status documentation at the moment of each filing. Because provisional application and formal entry into force can differ for a period of months, the legal characterization of a submission may depend on exactly when it was made. Recording the protocol’s status on the filing date — with a citation to the applicable notification or official announcement — creates a defensible record that protects the application if the regime is later questioned. This is a small administrative step, but it converts an ambiguous legal period into a documented one, and it applies equally to domestic milestones such as the entry into force of Resolution No. 2214 on January 8, 2026.

4. Practical recommendations

1. Establish a transition-period tracking mechanism covering three streams: announcements of the Eurasian Economic Commission, ratification progress in each member state, and synchronized amendments to Russian domestic rules. Assign a named owner and a fixed review cadence, so that signals from any stream reach the project plan in time to act.
2. Run product-line planning against the current deadlines and do not count a further postponement in the baseline scenario. Any buffer built into the schedule should come from earlier internal milestones, not from assumed regulatory relief.
3. For portfolios that must remain on the market after 2027, complete the Union-pathway feasibility assessment within 2026. The assessment should cover reference state selection, recognizing state candidates and the evidence gap, so that dossier work can begin without a preliminary study phase.

5. Verification checklist

• □ The key dates of both the 2021 and 2025 protocols have been recorded
• □ The status of the protocol (provisionally applied / formally in force) at the intended submission date has been confirmed
• □ Ratification progress of the remaining member states has been tracked
• □ Union-pathway assessment has been initiated for post-2027 market plans
• □ The plan does not default to an assumption of another postponement

Regulatory information verified as of October 29, 2026.

GRZAN supports medical device manufacturers entering the Russian market with end-to-end regulatory services covering both registration pathways: national registration under ПП РФ No. 1684, including route selection among clauses 63, 87 and 101, and EAEU registration under ЕЭК Decision No. 46, together with classification strategy support under Decision No. 173 as amended. Our team helps define the optimal route for each registration unit, prepare dossiers and testing plans, coordinate with RZN and expert institutions, and track transition deadlines through December 31, 2027. For tailored support on Russia market entry, pathway selection and dossier preparation, contact GRZAN at info@grzanglobal.com.